Key Takeaways

NeuroVision Imaging announced it has acquired Durin Life Sciences. The deal aims to combine blood-based biomarker diagnostics with retinal imaging and telehealth capabilities to create an integrated platform focused on earlier detection and management of neurodegenerative diseases, according to the companies.

Financial terms of the transaction were not disclosed.

The combined company will continue operating under the NeuroVision name and remain led by Steven Verdooner, CEO and co-founder of NeuroVision. The acquisition brings together Durin’s Duritect blood-based diagnostic platform with NeuroVision’s retinal imaging technology, telehealth infrastructure, and BrainHealth.net patient engagement platform.

Company executives said the merger is designed to accelerate development and commercialization of diagnostic tools for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and related neurological disorders.

“We’ve long believed that the future of neurodegenerative disease care begins with earlier and more accessible detection,” Mr. Verdooner said in a news release. “Durin’s blood-based biomarker platform represents an important advancement in that direction. By bringing together complementary strengths in diagnostics, technology and patient engagement, we believe we are uniquely positioned to help advance brain health at scale while supporting patients and families throughout the care journey.”

Durin Life Sciences developed Duritect, a suite of blood-based tests intended to support early detection and monitoring of neurodegenerative diseases. NeuroVision contributes its BrainHealth.net platform, which provides telehealth-enabled cognitive assessment, care navigation, and longitudinal brain health programs for patients and healthcare providers across the United States.

The companies said the integration of biomarker testing, imaging technologies, clinical infrastructure, and patient engagement tools could help improve access to earlier diagnosis and ongoing disease monitoring as demand for neurodegenerative care grows.

Ric Edelman, majority owner of Durin, will join the board of the combined company.